Calton & Associates’s Novavax NVAX Stock Holding History

Calton & Associates’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-1,863	Closed	-$21K	–	295
2019 Q1	$21K	Buy	1,863 +800	+75%	+$25.3K	0.01%	261
2018 Q4	$39K	Hold	1,063	–	–	0.01%	222
2018 Q3	$40K	Hold	1,063	–	–	0.01%	283
2018 Q2	$26K	Buy	+1,063	New	+$35.9K	0.01%	287
2018 Q1	–	Sell	-25	Closed	-$1K	–	966
2017 Q4	$1K	Buy	+25	New	+$610	﹤0.01%	1445

Other funds holding NVAX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Calton & Associates's NVAX Position: Q2 2019 in Review

Calton & Associates sold out of Novavax (NVAX) in Q2 2019, closing a stake of 1,863 shares — an estimated $21K sold.

Calton & Associates first reported a position in NVAX in Q4 2017 and held it in 5 quarters. The position peaked at $40K in Q3 2018. 81 funds tracked by Wall St. Rank hold NVAX as of Q2 2019.

Calton & Associates reported no remaining Novavax position as of Q2 2019 after selling out during the quarter.
Calton & Associates sold 1,863 Novavax shares in Q2 2019, an estimated $21K.
Calton & Associates first reported a position in Novavax in Q4 2017 and held it in 5 quarters.
Calton & Associates's Novavax position peaked at $40K in Q3 2018.
81 funds tracked by Wall St. Rank held Novavax as of Q2 2019.

Based on Calton & Associates's 13F filing for Q2 2019, filed 9 Jul 2019.